A Post-marketing Surveillance Study of Beyfortus (Nirsevimab) in Republic of Korea
← catalyst calendarNCT07200206 · readout in 1,134 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
3,000estimated
Sites
1
Country
South Korea
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-02 | actual | When the study began enrolling |
| Primary completion | 2029-09-26 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-09-26 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Respiratory Syncytial Virus
Intervention
- Biological: Nirsevimab — also filed as Beyfortus™
Primary outcomes
what the primary-completion date above is the date OFOccurence of Adverse Events (AEs)
measured Up to 180 days post dose
Occurence of Serious Adverse Events (SAEs)
measured Up to 180 days post dose
Occurrence of AE of special interest (AESI)
measured Up to 180 days post dose
Occurence of Adverse Drug Reaction (ADRs) as Specified in Approved Local Label
measured Up to 180 days post dose
Occurrence of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Infection (LRTI)
measured Up to 180 days post dose
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed